Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HRC 302

Drug Profile

HRC 302

Alternative Names: Autologous gamma-delta T cell infusion therapy; Gamma-delta T cell therapy - Hemosol BioPharma; HML-115

Latest Information Update: 13 Sep 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hemosol Corp
  • Developer Hemosol BioPharma
  • Class Antineoplastics; Cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Chronic myeloid leukaemia

Most Recent Events

  • 05 Sep 2007 Hemosol is seeking out-licensing and/or partnering opportunities for HRC 302 (http://www.hemosol.com/)
  • 19 Jul 2007 Hemosol Corp. is now a wholly-owned subsidiary of Catalyst Fund Ltd. Partnership II; the pharmaceutical business will be known as Hemosol BioPharma Inc.
  • 06 Nov 2000 Phase-I clinical trials for Chronic myeloid leukaemia in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top